Divi's shares rise 2% to 7,030 rupees, the top pharma index. HSBC upgrades to 'buy' with a 7,900-rupee target, citing tirzepatide demand and $450M revenue potential by 2030.

• HSBC upgrades Divi's to 'buy' from 'reduce', sets 7,900 rupee target highest of 24 analysts.
• Analysts expect $450M in revenue from peptides like GLP-1s by 2030, driven by tirzepatide demand.
• Divi's is the top performer in the pharma index this year, up 15% despite the index trading 0.4% lower.